Reneo Pharma Ltd   Report issue

For profit Phase 3
Founded: San Diego CA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03833128
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Reneo Pharma Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

ren001 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 1)

Glycogen Storage Disease Type V (Phase 1)

Mitochondrial Myopathies (Phase 3)

Muscular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1